Last reviewed · How we verify

NCT07085780

A Clinical Study to Assess the Safety and Effectiveness of Dharasana Lep in Patients With Mild to Moderate Muscular, Joint, or Rheumatic Pain

Completed NA Last updated 13 April 2026
What this trial tests

NA trial testing LEP in Musculoskeletal Pain in 35 participants. Completed in 15 September 2025.

Timeline
28 July 2025
Primary endpoint
15 September 2025
15 September 2025

Quick facts

Lead sponsorNovoBliss Research Pvt Ltd
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date28 July 2025
Primary completion15 September 2025
Estimated completion15 September 2025
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

NovoBliss Research Pvt Ltd — full company profile →

Who can join

Adults 25 to 65, any sex, with Musculoskeletal Pain or Rheumatic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Prospective, Open-Label, Single-Centre Interventional Study to Evaluate the Efficacy and Safety of Dharasana Lep in Patients with Mild to Moderate Musculoskeletal Pain and Rheumatoid Arthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of LEP

Trials testing the same drug.

Other recruiting trials for Musculoskeletal Pain

Currently open trials in the same condition.

Other NovoBliss Research Pvt Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing